ESR1 and breast cancer: In breast cancer, expression of FOXC2 is associated with and causal to chemotherapy resistance and metastasis in triple negative breast cancer (TNBC) [21, 22], a subtype defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression.